Medivir's history

Medivir was founded in 1988.

In 2014, Medivir took a strategic initiative to expand our therapeutic focus into oncology, where we are applying our expertise in protease inhibitors and nucleoside and nucleotide science to develop drugs to treat cancer.

2017

Groundbreaking top-line results from our initial phase IIa study in the MIV-711 osteoarthritis project

2016

  • Remetinostat and birinapant acquired, forming Medivir’s oncology clinical pipeline.

  • MIV-818 was selected as a candidate drug (CD) from the company’s project for the treatment of hepatocellular carcinoma.

  • The subsidiary BioPhausia (Nordic Brands) was divested to Karo Pharma AB.

  • The exclusive rights to the hepatitis C project, MIV-802, was outlicensed to Trek Therapeutics.

2015

  • The first oncology project within hepatocellular cancer was generated from the new focus area oncology.

  • SEK 600 million was transferred to the shareholders through a voluntary redemption program.

2014

  • MIV-802 was selected as a candidate drug for the treatment of hepatitis C infection.

  • Simeprevir approved in the EU and Russia for the treatment of adults with chronic hepatitis C.

  • Olysio and Adasuve launched in Sweden, Norway, Finland and Denmark.

2013

  • Simeprevir was approved for the treatment of patients with chronic hepatitis C in Japan, Canada and USA.

  • Registration application for Simeprevir submitted in Japan, USA and Europe.

2012

Positive phase III data reported for Simeprevir, confirming that treatment with Simeprevir in combination with interferon and ribavirin results in high cure rates, a good safety profile, and reduced treatment times.

2011

  • Global phase III trials of Simeprevir begin.

  • The North American marketing rights to Xerclear are sold to Meda.

  • BioPhausia acquired in order to strengthen the commercial platform.

2009

Xerclear approved for sale in certain European markets and the US market.

2006

Phase III trials of Xerclear begin.

2004

Hepatitis C agreement signed with Tibotec/Janssen for Simeprevir.

2000

Mimetrix UK acquired in order to strengthen and expand within the protease sphere.

1996

Medivir listed on the Stockholm Stock Exchange. Collaboration with Abbott begins.

1995

CCS, Clean Chemical Sweden AB, a Sweden-based manufacturer of skincare products, acquired.

1992

Collaboration agreements entered into with Eli Lilly for HIV, and with Wellcome.

1989

Collaboration agreement entered into with American Cyanamid for HIV.

1988

Medivir founded.